Scolaris Content Display Scolaris Content Display

Fenitoína tópica para el tratamiento de las úlceras por presión

Appendices

Appendix 1. Search strategies

The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)

#1 MeSH descriptor Pressure Ulcer explode all trees
#2 pressure NEXT (ulcer* or sore*):ti,ab,kw
#3 decubitus NEXT (ulcer* or sore*):ti,ab,kw
#4 (bed NEXT sore*) or bedsore:ti,ab,kw
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Phenytoin explode all trees
#7 phenytoin:ti,ab,kw
#8 (#6 OR #7)
#9 (#5 AND #8)

Ovid MEDLINE

1 exp Pressure Ulcer/
2 (pressure adj (ulcer* or sore*)).tw.
3 (decubitus adj (ulcer* or sore*)).tw.
4 (bedsore* or (bed adj sore*)).tw.
5 or/1‐4
6 exp Phenytoin/
7 phenytoin.tw.
8 or/6‐7
9 5 and 8
10 randomized controlled trial.pt.
11 controlled clinical trial.pt.
12 randomized.ab.
13 placebo.ab.
14 clinical trials as topic.sh.
15 randomly.ab.
16 trial.ti.
17 or/10‐16
18 (animals not (humans and animals)).sh
19 17 not 18
20 9 and 19

Ovid Embase

1 exp Decubitus/
2 (pressure adj (ulcer$ or sore$)).tw
3 (decubitus adj (ulcer* or sore*)).tw
4 (bedsore* or (bed adj sore*)).tw
5 or/1‐4
6 exp phenytoin/
7 exp phenytoin derivative/
8 phenytoin.tw
9 or/6‐8
10 5 and 9
11 Randomized controlled trials/
12 Single‐Blind Method/
13 Double‐Blind Method/
14 Crossover Procedure/
15 (random$ or factorial$ or crossover$ or cross over$ or cross‐over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
16 (doubl$ adj blind$).ti,ab.
17 (singl$ adj blind$).ti,ab.
18 or/11‐17
19 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
20 human/ or human cell/
21 and/19‐20
22 19 not 21
23 18 not 22
24 10 and 23
11 Clinical trial
12 Randomized controlled trials
13 Random Allocation
14 Single‐Blind Method
15 Double‐Blind Method
16 Cross‐Over Studies
17 Placebos
18 Randomized controlled trial$.tw
19 RCT.tw
20 Random allocation.tw
21 Randomly allocated.tw
22 Allocated randomly.tw
23 (allocated adj2 random).tw
24 Single blind$.tw
25 Double blind$.tw
26 ((treble or triple) adj blind$).tw
27 Placebo$.tw
28 Prospective Studies
29 or/11‐28
30 Case study
31 Case report.tw
32 Abstract report/ or letter
33 or/30‐32
34 29 not 33
35 animal
36 human
37 35 not 36
38 34 not 37
39 10 and 38

EBSCO CINAHL Plus

S1 (MH "Pressure Ulcer")
S2 TI (pressure ulcer* or pressure sore*) or AB (pressure ulcer* or pressure sore*)
S3 TI (bed sore* or bedsore*) or AB (bed sore* or bedsore*)
S4 TI decubitus or AB decubitus
S5 S1 or S2 or S3 or S4
S6 (MH "Phenytoin+")
S7 TI phenytoin or AB phenytoin
S8 S6 or S7
S9 S5 and S8
S10 MH "Clinical Trials+"
S11 PT Clinical trial
S12 TI (clinic* N1 trial) OR AB (clinic* N1 trial*)
S13 TI (singl* OR doubl* OR trebl* OR tripl*) OR TI (blind* OR mask*)
S14 AB (singl* OR doubl* OR trebl* OR tripl*) OR AB (blind* OR mask*)
S15 TI (randomi?ed control* trial*) OR AB (randomi?ed control* trial*)
S16 MH "Random Assignment"
S17 TI (random* allocat*) OR AB (random* allocat*)
S18 MH "Placebos"
S19 TI (placebo*) OR AB (placebo*)
S20 MH "Quantitative Studies"
S21 TI (allocat* random*) OR (allocat* random*)
S22 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21
S23 S9 AND S22

Appendix 2. Assessment of risk of bias in included studies

The Cochrane tool for assessing risk of bias

1. Was the allocation sequence randomly generated?
Low risk of bias

The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.

High risk of bias

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.

Unclear

Insufficient information about the sequence generation process provided to permit a judgement of low or high risk of bias.

2. Was the treatment allocation adequately concealed?
Low risk of bias

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomization); sequentially‐numbered drug containers of identical appearance; sequentially‐numbered, opaque, sealed envelopes.

High risk of bias

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. envelopes were unsealed, non‐opaque, or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear

Insufficient information provided to permit a judgement of low or high risk of bias. This is usually the case if the method of concealment is not described, or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

3. Blinding ‐ was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias

Any one of the following:

  • No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.

  • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non‐blinding of others unlikely to introduce bias.

High risk of bias

Any one of the following:

  • No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.

  • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, and the non‐blinding of others likely to introduce bias.

Unclear

Either of the following:

  • Insufficient information to permit judgement of low or high risk of bias.

  • The study did not address this outcome.

4. Were incomplete outcome data adequately addressed?
Low risk of bias

Any one of the following:

  • No missing outcome data.

  • Reasons for missing outcome data are unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).

  • Missing outcome data are balanced in numbers across intervention groups, with similar reasons for missing data across groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate.

  • For continuous outcome data, a plausible effect size (difference in means or standardised difference in means) among missing outcomes is not enough to have a clinically relevant impact on the observed effect size.

  • Missing data have been imputed using appropriate methods.

High risk of bias

Any one of the following:

  • Reason for missing outcome data are likely to be related to the true outcome, with either an imbalance in numbers or reasons for missing data across intervention groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is enough to induce clinically relevant bias in the intervention effect estimate.

  • For continuous outcome data, a plausible effect size (difference in means or standardised difference in means) among missing outcomes is enough to induce a clinically relevant bias in the observed effect size.

  • 'As‐treated' analysis done with a substantial departure of the intervention received from that assigned at randomization.

  • Potentially inappropriate application of simple imputation.

Unclear

Either of the following:

  • Insufficient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomized not stated, no reasons for missing data provided).

  • The study did not address this outcome.

5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias

Either of the following:

  • The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way.

  • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

High risk of bias

Any one of the following:

  • Not all of the study’s prespecified primary outcomes have been reported.

  • One or more primary outcomes is/are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified.

  • One or more reported primary outcomes was/were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).

  • One or more outcomes of interest in the review is/are reported incompletely so that they cannot be entered in a meta‐analysis.

  • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear

Insufficient information provided to permit a judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

6. Other sources of potential bias
Low risk of bias

The study appears to be free of other sources of bias.

High risk of bias

There is at least one important risk of bias. For example, the study:

  • had a potential source of bias related to the specific study design used; or

  • has been claimed to have been fraudulent; or

  • had some other problem.

Unclear

There may be a risk of bias, but there is either:

  • insufficient information to assess whether an important risk of bias exists; or

  • insufficient rationale or evidence that an identified problem will introduce bias

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies

Risk of bias summary: review authors' judgements about each risk of bias item for each included study
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Comparison 1 Topical phenytoin versus hydrocolloid dressing, Outcome 1 Proportion of ulcers healed within trial period.
Figuras y tablas -
Analysis 1.1

Comparison 1 Topical phenytoin versus hydrocolloid dressing, Outcome 1 Proportion of ulcers healed within trial period.

Comparison 2 Topical phenytoin versus simple dressing, Outcome 1 Proportion of ulcers healed within trial period.
Figuras y tablas -
Analysis 2.1

Comparison 2 Topical phenytoin versus simple dressing, Outcome 1 Proportion of ulcers healed within trial period.

Summary of findings for the main comparison. Topical phenytoin compared with hydrocolloid dressing for pressure ulcers

Topical phenytoin compared with hydrocolloid dressing for pressure ulcers

Patient or population: people with a pressure ulcer

Settings: family homes or nursing homes

Intervention: topical phenytoin

Comparison: hydrocolloid dressing

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with hydrocolloid dressing

Risk with topical phenytoin

Time to complete healing

See comments

See comments

The study data reported did not provide a suitable representation of the outcome of interest

Proportion of ulcers healed within trial period

(eight weeks)

714 per 1000

393 per 1000 (236 to 657)

RR 0.55 (0.33 to 0.92)

56 (1 study)

⊕⊕⊝⊝
low1

Adverse events

See comments

See comments

Not estimable

84 (2 studies)

No adverse drug reactions or interactions were detected in the included RCTs.

Pain

See comments

See comments

Not

estimable

28 (1 study)

Minimal pain was reported in all groups in one study. Study authors made this statement without any data to support it.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SD: standard deviation

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1. Downgraded two levels: serious limitation (risk of bias), serious imprecision (small number of events )

Figuras y tablas -
Summary of findings for the main comparison. Topical phenytoin compared with hydrocolloid dressing for pressure ulcers
Summary of findings 2. Topical phenytoin compared with triple antibiotic ointment for pressure ulcers

Topical phenytoin compared with triple antibiotic ointment for pressure ulcers

Patient or population: people with a pressure ulcer

Settings: nursing homes

Intervention: topical phenytoin

Comparison: triple antibiotic ointment

Outcomes

Anticipated absolute effects (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with triple antibiotic ointment

Risk with topical phenytoin

Time to complete healing

See comments

See comments

The study data reported did not provide a suitable representation of the outcome of interest

Proportion of ulcers healed within trial period (eight weeks)

See comments

See comments

This outcome was not reported for this comparison

Adverse events

See comments

See comments

Not estimable

28 (1 study)

No adverse drug reactions or interactions were detected in the included RCT.

Pain

See comments

See comments

Not estimable

28 (1 study)

Minimal pain was reported in all groups in one study. Study authors made this statement without any data to support it.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SD: standard deviation

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

Figuras y tablas -
Summary of findings 2. Topical phenytoin compared with triple antibiotic ointment for pressure ulcers
Summary of findings 3. Topical phenytoin group compared with a simple dressing for pressure ulcers

Topical phenytoin compared with a simple dressing for pressure ulcers

Patient or population: people with a pressure ulcer

Settings: family homes or nursing homes, and a hospital

Intervention: topical phenytoin

Comparison: a simple dressing

Outcomes

Anticipated absolute effects (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with a simple dressing

Risk with topical phenytoin

Time to complete healing

See comments

See comments

This outcome was not reported for this comparison

Proportion of ulcers healed within trial period (eight weeks)

296 per 1000

394 per 1000 (187 to 824)

RR 1.33 (0.63 to 2.78)

55 (1 study)

⊕⊝⊝⊝

very low1

Adverse events

See comments

See comments

Not estimable

81 (2 studies)

No adverse drug reactions or interactions were detected in the included RCTs.

Pain

See comments

See comments

This outcome was not reported for this comparison.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SD: standard deviation

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1. Downgraded three levels: once for serious limitation (risk of bias), and twice for very serious imprecision (small number of events and a wide confidence interval which includes the possibility of both increased healing and reduced healing)

Figuras y tablas -
Summary of findings 3. Topical phenytoin group compared with a simple dressing for pressure ulcers
Comparison 1. Topical phenytoin versus hydrocolloid dressing

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Proportion of ulcers healed within trial period Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 1. Topical phenytoin versus hydrocolloid dressing
Comparison 2. Topical phenytoin versus simple dressing

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Proportion of ulcers healed within trial period Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 2. Topical phenytoin versus simple dressing